Jaan Biotherapeutics, LLC is a private company that is developing novel therapies to activate the cardiac regeneration process in diseased hearts using proprietary technology. The technology manipulates microRNAs to activate an endogenous cardiac muscle regeneration process which has been shut down in the adult human heart during evolution.

Our current focus is Ischemic Heart Disease (IHD), but the therapy can be applied to many cardiac diseases where cardiac muscle regeneration is required, such as cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). We are also developing a therapeutic for hypertrophic cardiomyopathy (HCM). We aim to initiate clinical testing in 2025 for our lead programs. Since 2017, Jaan Biotherapeutics has received three National Institutes of Health Small Business grants to support their drug development pipeline.

Jaan Biotherapeutics has over 30 patents, with five US issued patents covering our drug design and targets.